Reata Pharma (NQ: RETA )
93.02 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Press Releases about Reata Pharma
FDA Grants Approval of Reata Pharmaceuticals’ (NASDAQ: RETA) SKYCLARYS Drug, Making the First and Only Drug for Friedreich’s Ataxia
March 01, 2023
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization
Via Spotlight Growth
Exposures Product Safety
NASDAQ:RETA Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Reata Pharmaceuticals, Inc.
May 10, 2022
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc.
Final Deadline Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 18, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following